The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Low-Abundance Drug-Resistant Viral Variants in Chronically HIV-Infected, Antiretroviral Treatment–Naive Patients Significantly Impact Treatment Outcomes
Abstract
BACKGROUND: Minor (i.e., <20% prevalence) drug-resistant human immunodeficiency virus (HIV) variants may go undetected, yet be clinically important. OBJECTIVES: To compare the prevalence of drug-resistant variants detected with standard and ultra-deep sequencing (detection down to 1% prevalence) and to determine the impact of minor resistant variants on virologic failure (VF). METHODS: The Flexible Initial Retrovirus Suppressive Therapies (FIRST) Study (N = 1397) compared 3 initial antiretroviral therapy (ART) strategies. A random subset (n = 491) had baseline testing for drug-resistance mutations performed by use of standard sequencing methods. Ultra-deep sequencing was performed on samples that had sufficient viral content (N = 264). Proportional hazards models were used to compare rates of VF for those who did and did not have mutations identified. RESULTS: Mutations were detected by standard and ultra-deep sequencing (in 14% and 28% of participants, respectively; P < .001). Among individuals who initiated treatment with an ART regimen that combined nucleoside and nonnucleoside reverse-transcriptase inhibitors (hereafter, "NNRTI strategy"), all individuals who had an NNRTI-resistance mutation identified by ultra-deep sequencing experienced VF. When these individuals were compared with individuals who initiated treatment with the NNRTI strategy but who had no NNRTI-resistance mutations, the risk of VF was higher for those who had an NNRTI-resistance mutation detected by both methods (hazard ratio [HR], 12.40 [95% confidence interval {CI}, 3.41-45.10]) and those who had mutation(s) detected only with ultra-deep sequencing (HR, 2.50 [95% CI, 1.17-5.36]). CONCLUSIONS: Ultra-deep sequencing identified a significantly larger proportion of HIV-infected, treatment-naive persons as harboring drug-resistant viral variants. Among participants who initiated treatment with the NNRTI strategy, the risk of VF was significantly greater for participants who had low- and high-prevalence NNRTI-resistant variants.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DNA sequencing with chain-terminating inhibitors
Sanger, F., Nicklen, S., & Coulson, A. R. (1977) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.74.12.5463 · Cited by 68,572
Genome sequencing in microfabricated high-density picolitre reactors
Margulies, M., Egholm, M., Altman, W. E., Attiya, S., Bader, J. S., Bemben, L. A., Berka, J., Braverman, M. S., Chen, Y.-J., Chen, Z., et al. (2005) · Nature · doi:10.1038/nature03959 · Cited by 7,693
Self-citationGuidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents
(1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-12_part_2-199806151-00003 · Cited by 5,209
UPDATE ON DRUG RESISTANCE MUTATIONS IN HIV-1
&NA; (2001) · Infectious Diseases in Clinical Practice · doi:10.1097/00019048-200106000-00020 · Cited by 1,660
Human Immunodeficiency Virus Reverse Transcriptase and Protease Sequence Database
Shafer, R. W., Stevenson, D., & Chan, B. (1999) · Nucleic Acids Research · doi:10.1093/nar/27.1.348 · Cited by 907
Human immunodeficiency virus reverse transcriptase and protease sequence database
Rhee, S.-Y. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg100 · Cited by 817
Wang, C., Mitsuya, Y., Gharizadeh, B., Ronaghi, M., & Shafer, R. W. (2007) · Genome Research · doi:10.1101/gr.6468307 · Cited by 408
Johnson, J. A., Li, J.-F., Wei, X., Lipscomb, J., Irlbeck, D., Craig, C., Smith, A., Bennett, D. E., Monsour, M., Sandstrom, P., et al. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050158 · Cited by 371
Thomas, R. K., Nickerson, E., Simons, J. F., Jänne, P. A., Tengs, T., Yuza, Y., Garraway, L. A., LaFramboise, T., Lee, J. C., Shah, K., et al. (2006) · Nature Medicine · doi:10.1038/nm1437 · Cited by 361
Self-citationUpdate of the drug resistance mutations in HIV-1: Fall 2005.
Johnson, V. A., Brun‐Vézinet, F., Clotet, B., Conway, B., Kuritzkes, D. R., Pillay, D., Schapiro, J., Telenti, A., & Richman, D. D. (2005) · PubMed · Cited by 333
DNA bar coding and pyrosequencing to identify rare HIV drug resistance mutations
Hoffmann, C., Minkah, N., Leipzig, J., Wang, G., Arens, M. Q., Tebas, P., & Bushman, F. D. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm435 · Cited by 219
MacArthur, R. D., Novak, R. M., Peng, G., Chen, L., Xiang, Y., Hullsiek, K. H., Kozal, M. J., van den Berg-Wolf, M., Henely, C., Schmetter, B., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69861-9 · Cited by 139
Self-citationZaccarelli, M., Tozzi, V., Lorenzini, P., Trotta, M. P., Forbici, F., Comandini, U. V., Gori, C., Narciso, P., Perno, C. F., & Antinori, A. (2005) · AIDS · doi:10.1097/01.aids.0000174455.01369.ad · Cited by 137
Expert Committee on Biological Standardization
&NA; (1964) · The American Journal of the Medical Sciences · doi:10.1097/00000441-196404000-00041 · Cited by 99
Quantitative Detection of Low-Copy-Number mRNAs Differing at Single Nucleotide Positions
Stenman, J. J. E., Lintula, S., Rissanen, O., Finne, P., Hedström, J., Palotie, A. V., & Orpana, A. (2003) · BioTechniques · doi:10.2144/03341dd05 · Cited by 20
Chapter 5 The 454 Life Sciences Picoliter Sequencing System
Margulies, M., Jarvie, T. P., Knight, J., & Simons, J. F. (2007) · Perspectives in bioanalysis · doi:10.1016/s1871-0069(06)02005-2 · Cited by 14
Self-citation
Cited by
Domingo, E., Sheldon, J., & Perales, C. (2012) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.05023-11 · Cited by 1,009
Antiviral Drug Resistance of Human Cytomegalovirus
Lurain, N. S., & Chou, S. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00009-10 · Cited by 596
Hajibabaei, M., Shokralla, S., Zhou, X., Singer, G. A. C., & Baird, D. J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017497 · Cited by 584
“Other studies, especially studies targeting rare HIV mutants have used this strategy to detect low abundance virus genes in clinical samples [18].”
Johnson, J. A., Li, J.-F., Wei, X., Lipscomb, J., Irlbeck, D., Craig, C., Smith, A., Bennett, D. E., Monsour, M., Sandstrom, P., et al. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050158 · Cited by 371
Metadata
- Authors
- Simen, B. B., Simons, J. F., Hullsiek, K. H., Novak, R. M., MacArthur, R. D., Baxter, J. D., Huang, C., Lubeski, C., Turenchalk, G. S., Braverman, M. S., Desany, B., Rothberg, J. M., Egholm, M., Kozal, M. J., & Terry Beirn Community Programs for Clinical Research on, A. I. D. S.
- Venue
- Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-03-01
- Volume
- 199
- Issue
- 5
- Pages
- 693-701
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- OpenAlex
- W1966063036
- Cited by
- 392
- References
- 16
- FWCI
- 34.14
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.